We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.38B
AUM Growth
+$319M
Cap. Flow
-$50.3M
Cap. Flow %
-0.6%
Top 10 Hldgs %
33.94%
Holding
161
New
20
Increased
28
Reduced
35
Closed
14

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$304M
2
ELV icon
Elevance Health
ELV
+$123M
3
XRAY icon
Dentsply Sirona
XRAY
+$102M
4
AGN
Allergan plc
AGN
+$95.1M
5
INSP icon
Inspire Medical Systems
INSP
+$78.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$185M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$154M
3
ABBV icon
AbbVie
ABBV
+$145M
4
THC icon
Tenet Healthcare
THC
+$119M
5
BMY icon
Bristol-Myers Squibb
BMY
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.69%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
126
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.01M 0.05%
141,900
– –
STIM icon
127
Neuronetics
STIM
$131M
$3.99M 0.05%
+150,000
New +$4.08M
SRRA
128
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.75M 0.04%
31,678
-23,415
-43% -$2.35M
KIDS icon
129
OrthoPediatrics
KIDS
$511M
$3.65M 0.04%
136,900
-288,300
-68% -$6.15M
AKRX
130
CALL
DELISTED
Akorn Inc
AKRX
$3.32M 0.04%
+200,000
New +$3.07M
SNDX icon
131
Syndax Pharmaceuticals
SNDX
$1.68B
$3.07M 0.04%
437,000
– –
TSRO
132
DELISTED
TESARO, Inc.
TSRO
$2.99M 0.04%
67,281
– –
GWPH
133
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.93M 0.03%
21,000
-53,000
-72% -$7.53M
IRWD icon
134
CALL
Ironwood Pharmaceuticals
IRWD
$602M
$2.87M 0.03%
179,100
– –
ADMS
135
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
$2.58M 0.03%
+100,000
New +$2.77M
AUPH icon
136
Aurinia Pharmaceuticals
AUPH
$1.92B
$943K 0.01%
167,419
-458,856
-73% -$2.56M
BLRX
137
BioLineRX
BLRX
$12.3M
$924K 0.01%
1,731
– –
AFMD
138
DELISTED
Affimed
AFMD
$539K 0.01%
32,665
– –
SCTL
139
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$539K 0.01%
+119,703
New +$950K
ALIM
140
DELISTED
Alimera Sciences
ALIM
$245K ﹤0.01%
16,667
– –
XYLO
141
DELISTED
Xylo Technologies
XYLO
$74K ﹤0.01%
375
– –
ABBV icon
142
AbbVie
ABBV
$471B
– –
-1,527,500
Closed -$145M
BMY icon
143
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-200,000
Closed -$12.7M
EXEL icon
144
CALL
Exelixis
EXEL
$14.1B
– –
-150,000
Closed -$3.32M
MCRB icon
145
Seres Therapeutics
MCRB
$46M
– –
-4,761
Closed -$699K
NVO
146
CALL
Novo Nordisk
NVO
$228B
– –
-400,000
Closed -$9.85M
SRPT icon
147
CALL
Sarepta Therapeutics
SRPT
$1.62B
– –
-50,000
Closed -$3.71M
TEVA icon
148
PUT
Teva Pharmaceuticals
TEVA
$39.4B
– –
-200,000
Closed -$3.42M
VTRS icon
149
CALL
Viatris
VTRS
$20.8B
– –
-250,000
Closed -$10.3M
XNCR icon
150
Xencor
XNCR
$1.44B
– –
-612,500
Closed -$18.4M
3 4 5
6
7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2018 Portfolio in Review

As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
  • OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
  • OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
  • OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
  • OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
  • OrbiMed opened 20 new positions and closed 14 in Q2 2018.
  • OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.